LeonaBio, Inc. (LONA) Fair Value 2026

LONA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-08-28, LeonaBio, Inc. (LONA) trades at $7.94. QOC: 4.8/10. Value Trap Risk: 43/100 (WARN). 1/13 models active.

Key Facts

Ticker
LONA
Price
$7.94
Quality Score
4.8/10
Value Trap Risk
43/100
Models Active
1/13
Last Updated
Strength: ML-RIV suggests +40.3% upside with 54% confidence
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give LONA?

1 Intrinsic Value Models vs. Current Price ($7.94)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $11.14 +40.3%

All Models Active

All 1 models are displayed above.

What Is LeonaBio, Inc. (LONA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, LeonaBio, Inc.'s intrinsic value is estimated at a median fair value of $11.14. At a current market price of $7.94, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +40.3%.

What Do the Models Say About LONA?

1 of 13 models are currently active for LONA. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does LONA Rank in Biotechnology?

Among 625 Biotechnology stocks, LONA ranks #380 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For LeonaBio, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is LONA a Value Trap?

CirclFi's Value Trap algorithm assigns LONA a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for LeonaBio, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, LeonaBio, Inc. scores 4.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LONA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LONA's 1 active models, average confidence is 54%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy LeonaBio, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ATOSAtossa Therapeutics, Inc.QOC 4.8ANNXAnnexon, Inc.QOC 4.8MLYSMineralys Therapeutics, Inc.QOC 4.8PVLAPalvella Therapeutics, Inc.QOC 4.8LYELLyell Immunopharma, Inc.QOC 4.8AGENAgenus Inc.QOC 4.8MBIOMustang Bio, Inc.QOC 4.0BCYCBicycle Therapeutics plcQOC 6.7IBIOiBio, Inc.QOC 5.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ATOS · ANNX · MLYS · PVLA · LYEL · AGEN · MBIO · BCYC · IBIO · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to LONA?

6 companies across all industries closest to LONA’s Quality of Company score of 4.8/10.

RGCRegencell Bioscience Holdings LimitedQOC 4.8XXITwenty One Capital, Inc.QOC 4.8SRCOSparta Commercial Services, Inc.QOC 4.8ALURAllurion Technologies Inc.QOC 4.8GUTThe Gabelli Utility TrustQOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RGC · XXI · SRCO · ALUR · GUT · NVDA

Where Does LONA Sit in CirclFi's Biotechnology Rankings?

LONA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About LeonaBio, Inc.’s Valuation?

What is LeonaBio, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for LeonaBio, Inc. (LONA). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LONA overvalued or undervalued right now?

At $7.94, 1 of 1 active models suggest LONA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits LeonaBio, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.8 mean for LONA?

LeonaBio, Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on LONA?

CirclFi analyzes LONA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is LONA a value trap in 2026?

LeonaBio, Inc.'s Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns LeonaBio, Inc. (LONA) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/LONA/ · Methodology
Primary sources for this LONA valuation
  • Financial statements: LeonaBio, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001620463) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LONA as of ; valuations recomputed .